Domo reported Q2 earnings beating analyst expectations with $0.02 adjusted EPS and $79.7 million in sales, but provided conservative guidance that disappointed investors, leading to a significant stock price decline.

Domo announced a strategic collaboration with Amazon Web Services to provide AI-powered business solutions, leveraging generative AI technology to help customers improve business outcomes.

Domo, an AI and Data Products platform, announced that it will present at the D.A. Davidson Technology Summit on June 11, 2025. The company's presentation will be available via a live webcast on its Investor Relations website.

U.S. stocks traded mixed as investors weighed fiscal concerns, sending Treasury yields higher and the dollar lower. Bitcoin surged past $109,000 after JPMorgan announced it will allow client purchases without custody services.

Domo, an AI and data products platform, announced that it will present at the TD Cowen 53rd Annual Technology, Media & Telecom Conference on May 29, 2025.

The Business Intelligence market is projected to grow at a CAGR of 10.09% from 2024 to 2032, driven by the adoption of AI, analytics, and cloud solutions, as well as rising demand for security, real-time insights, and automation.

The enterprise data management market is expected to grow from $95.3 billion in 2023 to $246.98 billion by 2032, driven by rising data complexity, the need for data-driven decision-making, and the adoption of cloud-based solutions.

The global data monetization market is projected to reach $16.98 billion by 2031, driven by the increasing volume of data and digital transformation. Key industry segments include data monetization tools and the IT/telecommunications sector. North America is expected to dominate the market due to the adoption of data-driven decision-making.

Domo, Inc. (NASDAQ:DOMO) reported mixed first-quarter financial results and issued second-quarter guidance below estimates on Thursday. Domo posted adjusted loss of 33 cents per share, wider than market expectations for a loss of 23 cents per share. The company's sales came in at $80.103 million versus estimates of $79.492 million, according to data from Benzinga Pro. “We’re hyper-focused on returning to growth, and feel optimistic about early signals from our strategic initiatives ...Full story available on Benzinga.com

DOMO earnings call for the period ending March 31, 2024.

Domo (DOMO) delivered earnings and revenue surprises of -43.48% and 0.67%, respectively, for the quarter ended April 2024. Do the numbers hold clues to what lies ahead for the stock?

Shares of Marvell Technology, Inc. (NASDAQ: MRVL) fell sharply during Friday’s session after the company reported fourth-quarter financial results and issued weak Q1 guidance. Marvell said fourth-quarter revenue increased 1% year-over-year to $1.427 billion, which beat the consensus estimate of $1.42 billion. The chip designer reported quarterly earnings of 46 cents per share, which was in line with analyst estimates. Marvell sees first-quarter revenue of $1.15 billion, plus or minus 5%, versus estimates of $1.371 billion. The company sees first-quarter adjusted earnings of 23 cents per share, plus or minus 5 cents per share, versus estimates of 40 cents per share. The company authorized a $3 billion buyback. Marvell Technology shares dipped 9.6% to $76.91 on Friday. Here are some other stocks moving in today's mid-day session. Gainers Ainos, Inc. (NASDAQ: AIMD) jumped 140% to $2.6899 after dipping 18% on Thursday. Psyence Biomedical Ltd. (NASDAQ: PBM) shares climbed 139% to $3.0350. Psyence Biomedical recently announced its subsidiary, Psyence Australia, received Human Research Ethics Committee approval to initiate its Phase IIb study. Safe and Green Development Corporation (NASDAQ: SGD) shares jumped 138% to $1.57 after the company announced financing for the Norman Berry Expansion in Atlanta, Georgia. MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) shares climbed 48.5% to $1.36. MIRA Pharmaceuticals, last month, announced a research collaboration with Pharmaseed to research and evaluate Ketamir for patients with major depressive disorder and post-traumatic stress disorder. CERo Therapeutics Holdings, Inc. (NASDAQ: CERO) shares climbed 35.4% to $4.17 after surging over 20% on Thursday. CERo Therapeutics recently announced the publication of preclinical research analyzing CER-1236 in targeting Acute Myelogenous Leukemia tumor cells from human patients. Willdan Group, Inc. (NASDAQ: WLDN) gained 30.4% to $25.89 after the company reported better-than-expected fourth-quarter financial results and issued FY24 guidance above estimates. Also, the company secured a contract worth approximately $30 million to $50 million over three years. The Joint Corp. (NASDAQ: JYNT) gained 29% to $11.80 following fourth-quarter results. Smith & Wesson Brands, Inc. (NASDAQ: SWBI) jumped 25.8% to $16.91 after the company reported better-than-expected third-quarter financial results. Research Frontiers Incorporated ...